Article
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
The Lancet. Oncology - 1 Apr 2014
Larkin James, Del Vecchio Michele, Ascierto Paolo A, Krajsova Ivana, Schachter Jacob, Neyns Bart, Espinosa Enrique, Garbe Claus, Sileni Vanna Chiarion, Gogas Helen, Miller Wilson H, Mandalà Mario, Hospers Geke A P, Arance Ana, Queirolo Paola, Hauschild Axel, Brown Michael P, Mitchell Lada, Veronese Luisa, Blank Christian U
Abstract excerpt
BACKGROUND: The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival (PFS), and overall survival in patients with metastatic melanoma that has a BRAF(V600) mutation. We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options. METHODS: In an open-label, multicentre...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.